DOCSLIB.ORG

158273472.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ANNUAL .2003REPCOLD SPRING HARBOR LABORATORY .1; ANNUAL REPORT 2003 © 2004 by Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory One Bungtown Road Cold Spring Harbor, New York 11724 Web Site: www.cshl.edu Managing Editors Jeff Picarello, Lisa Becker Production Editor Rena Steuer Copy Editor Dorothy Brown Development Manager Jan Argentine Project Coordinators Maria Falasca, Nora Rice Production Manager Denise Weiss Desktop Editor Susan Schaefer Nonscientific Photography Miriam Chua, Bill Geddes Cover Designer Denise Weiss Book Designer Emily Harste Front cover: McClintock Laboratory (right) and Carnegie Library (left) (photos by Miriam Chua) Back cover: Magnolia Kobus on grounds of Cold Spring Harbor Laboratory (photo by Bruce Stillman) Section title pages: Miriam Chua Contents Officers of the Corporation/Board of Trusteesiv-v Governancevi Committees vii Edwin Marks (1926-2003) viii PRESIDENT'S REPORT Highlights5 CHIEF OPERATING OFFICER'S REPORT 25 50TH ANNIVERSARY OF THE DOUBLE HELIX 29 RESEARCH 47 Cancer: Gene Expression 49 Cancer: Genetics 74 Cancer: Cell Biology 106 Bioinformatics and Genomics 134 Neuroscience152 Plant Development and Genetics 199 CSHL Fellows 212 Author Index 217 WATSON SCHOOL OF BIOLOGICAL SCIENCES 219 Dean's Report 221 Courses 238 Undergraduate Research Program245 Partners for the Future 248 Nature Study 249 COLD SPRING HARBOR LABORATORY MEETINGS AND COURSES 251 Academic Affairs253 Symposium on Quantitative Biology 255 Meetings 258 Postgraduate Courses295 Seminars 353 BANBURY CENTER 355 Director's Report357 Meetings 365 DOLAN DNA LEARNING CENTER 403 Director's Report 405 Workshops, Meetings, and Collaborations 418 COLD SPRING HARBOR LABORATORY PRESS 425 Publications 426 Executive Director's Report 427 FINANCE 431 History of the CSHL Endowment 433 Financial Statements 444 Financial Support448 Grants448 Institutional Advancement 457 Capital and Program Contributions 458 Watson School of Biological Sciences Capital Campaign 459 Annual Contributions 460 LABORATORY STAFF 474 III Officers of the Corporation William R. Miller, Chairman Bruce Stillman, Ph.D., President and Chief Executive Officer Edwin S. Marks, Vice Chairman James D. Watson, Ph.D., Chancellor Lola N. Grace, Secretary/Treasurer W. Dillaway Ayres, Jr., Chief Operating Officer G. Morgan Browne, Chief Financial Officer Board of Trustees Scientific Trustees David Botstein, Ph.D. Titia de Lange, Ph.D. Edward E. Harlow, Ph.D. Jeff Hawkins pSuosavosnt,Hockfuoltd; Ph.D. Director and Mthony B. Eunin Leon Hess Pro fessor,The Chairman for the Dept of Biological Chief Technology Offlcer, palmOne, Inc. Professor of Genomics, Lewis-Siger RockefellerUniversity Chemistry and Molecular Pharmacology, Institute, Princeton University Harvard Medical School Susan Lee Lindquist, Ph.D. Lorne Mendell, Ph.D. Charles J. Sherr, M.D., Ph.D. Bruce Stillman, Ph.D. Director Whitehead Institute for Distinguished Professor/Chairman, Chairman, Dept. of Tumor Cell President and CEO, Biomedical Research, Massachusetts Dept of Neurobiology & Behavior, Biology, HHMI/St. Jude Children's Co, Spring Harbor Laboratory Institute of Technology Stony Brook University Research Hospital Individual Trustees Trudy H. Calabrese Kristina Perkin Davison Jacob Goldfield Amy Goldman, Ph.D. Lola N. Grace Lloyd Harbor, New York Partner, Europe Capital, LLC New York, New York Rhinebeck New York Managing Director, Stedng Grace Capita/ Management Charles E. Harris Robert D. Lindsay Edwin S. Marks Eduardo G. Mestre William R. Miller Chairman and CEO, Co-Managing Partner, President, Chairman,Investment Banking, New York, New York Harris & Harris Group, Inc. Goldberg Lindsay & Co. Carl Marks & Co, Inc Citigroups Global Markets, Inc. iv Douglas P. Morris Thomas C. Quick William S. Robertson Howard Solomon Arthur M. Spiro Chairman and CEO, Palm Beach, Florida Naples, Florida Charman of the Board and Kings Point, New York Universal Music Group CEO, Forest Laboratories Alan C. Stephenson James M. Stone Edward Travagilanti James D. Watson, Ph.D. Roy J. Zuckerberg Partner, Cravath Swaine & CEO, The Plymouth Rock Lloyd Harbor, New York Chancellor, Senior Director, Goldman Moore, LLP Company Cold Spring Harbor Laboratory Sachs and Company Honorary Trustees Bayard Clarkson, M.D. John P. Cleary, Esq. Charles F. Dolan Helen Ann Dolan Martha Fadsh Gerry Memorial Sloan-Kettering Locust ValleY, New Y.. Oyster Bay, New York Oyster Bay, New York Mill Neck, New York Cancer Center, New York H. Bentley Glass Evelyn H. Lauder Maly D. Lindsay David L. Luke Ill New York, New Yo. New York, New York Boulder, Colorado New York, New Y. Es. Lauder Companies, Inc. William E. Murray Wendy Vander Pool Russell New York, New York Oyster Bay, New York Governance The Laboratory is governed by a Board of Trustees of up to 35 members which meets three or four times a year. Authority to act for the Board of Trustees between meetings is vested in the Executive Committee of the Board of Trustees. The Executive Committee is composed of the Officers of the Board and any other members who may be elected to the Executive Committee by the Board of Trustees. Additional standing and ad hoc committees are appointed by the Board of Trustees to provide guidance and advice in specific areas of the Laboratory's operations. Representation on the Board of Trustees itself is divided between business and community leaders and scientists from major educational and research institutions. The Laboratory is chartered as an educational and research institution by the Board of Regents of the Education Department of the State of New York. It is authorized to operate a graduate program under the name "Cold Spring Harbor Laboratory, Watson School of Biological Sciences" and thereat to confer the degrees of Doctor of Philosophy (Ph.D.), Master of Science (M.S.), and Doctor of Science (Sc.D.), Honorary. It is designated as a "public charity" under Section 501(0(3) of the Internal Revenue Code. Grace Auditorium vi Committees Audit Lawrence Scherr, M.D. W. Dillaway Ayres, Jr. Bruce Stillman, Ph.D. Eduardo G. Mestre Charles E. Harris, Chair William R. Miller William R. Miller Bruce Stillman, Ph.D. Arthur M. Spiro Executive Committee William R. Miller, Chair Building W. Dillaway Ayres, Jr. Banbury Center, G. Morgan Browne Helen A. Dolan, Chair Robertson/Meier Houses Trudy Calabrese Arthur Brings Lola N. Grace William S. Robertson, Chair John P. Cleary Esq. Edwin S. Marks W. Dillaway Ayres, Jr. Mary D. Lindsay Eduardo G. Mestre Jan Witkowski, Ph.D. Nancy Marks Arthur M. Spiro James D. Watson, Ph.D. Wendy Vander Poel Russell Bruce Stillman, Ph.D. Elizabeth Watson Robertson Research Fund Finance Commercial Relations Carl Schafer, Chair Lola N. Grace, Chair W. Dillaway Ayres, Jr. William R. Miller, Chair W. Dillaway Ayres, Jr. Hollis Cline, Ph.D. W. Dillaway Ayres, Jr. G. Morgan Browne Lola N. Grace G. Morgan Browne Jacob Goldfield William R. Miller John P Cleary, Esq. Charles E. Harris Bruce Stillman, Ph.D. John P. Maroney Robert D. Lindsay Bruce Stillman, Ph.D. Edwin S. Marks William R. Miller Family Representatives Compensation William S. Robertson Katherine Ernst Lari Russo Walter Meier, M.D. William R. Miller, Chair Howard Solomon William S. Robertson Lola N. Grace Charles E. Harris Investment Tenure and Appointments Lola N. Grace, Chair Dolan DNA Learning Center Titia de Lange, Ph.D. W. Dillaway Ayres, Jr. Edward Harlow, Ph.D. Arthur M. Spiro, Chair Jacob Goldfield Susan Hockfield, Ph.D. Marion Wood Ahmed Edwin S. Marks Susan Lindquist, Ph.D. W. Dillaway Ayres, Jr. William S. Robertson Edward Chernoff Lorne Mendell, Ph.D. Edward M. Scolnick, M.D. Lola N. Grace Nominating Suzanne Kleinknecht Charles J. Sherr, M.D., Ph.D. David Mick los Robert D. Lindsay, Chair Bruce Stillman, Ph.D. Committees as of November, 2003, VII Edwin S. Marks (1926-2003) First and foremost a family man, Edwin Marks gave to others as he did to those nearest to him. Successful in business, a generous philanthropist, provider of sound advice, and a man with broad interests and intellect, Edwin Marks died on April 24, 2003. At the time of his death, he was Vice Chairman of our Board of Trustees and a most devoted and valued advi- sor. Born and raised in Brooklyn on the same block as his future wife, Nancy, Edwin's forma- tive years occurred as his father founded and developed a successful banking business. Established in the year before Edwin was born, Carl Marks & Co. initially traded foreign secu- rities but later, under Edwin's skilled leadership, expanded into a diverse banking enterprise including venture capital, private equities, corporate development, real estate, and financial advise and planning. Despite-or perhaps because of-his father's success, upon entering college, Edwin did not intend to pursue a career in banking. After schooling at Brooklyn's Poly Prep Country Day School, Edwin initially studied at Princeton, but a yearning to enter into the diplomatic core caused a change in direction that greatly influenced his future. Following the advice of a fam- ily friend, he transferred to the United States Military Academy at West Point. This surprising turn of events uprooted a potentially comfortable academic life at Princeton, but due to influ- ences from both West Point and General Maxwell Taylor, Edwin stretched himself beyond his upbringing. It was clear from discussions and e-mail correspondence with him that West Point was a special place never to leave Edwin's universe. Upon graduating, he married Nancy, and together, they set off on an adventure that lasted 54 years. Initially stationed in El Paso, Texas and Anchorage, Alaska, environs far from the neigh- borhood in Brooklyn, Edwin began to use his considerable skills in an eight-year military career. His capabilities as an entrepreneur, leader, and diplomat emerged. He enjoyed serv- ing his country. viii In 1953, when his father's health began to fail, Edwin's life took what must have been an unexpected turn when he joined his father's Wall Street firm, working his way up from the bottom to learn the business and eventually head the company.
Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September

    ANNUAL REVIEW 1 October 2005–30 September

    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
  • Clinical Significance and Biological Role of L1 Cell Adhesion Molecule In

    Clinical Significance and Biological Role of L1 Cell Adhesion Molecule In

    www.nature.com/bjc ARTICLE Molecular Diagnostics Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer Takashi Ichikawa1, Yoshinaga Okugawa 1, Yuji Toiyama1, Koji Tanaka1, Chengzeng Yin1, Takahito Kitajima1, Satoru Kondo1, Tadanobu Shimura1, Masaki Ohi1, Toshimitsu Araki1 and Masato Kusunoki1 BACKGROUND: L1 cell adhesion molecule (L1CAM) is highly expressed in malignant tumours and might play a pivotal role in tumour progression. METHODS: We analysed by immunohistochemistry L1CAM protein expression in formalin-fixed, paraffin-embedded specimens from 309 GC patients. We performed propensity score matching (PSM) analysis to clarify the prognostic impact of L1CAM in GC patients. We evaluated L1CAM gene expression in fresh frozen specimens from another group of 131 GC patients to establish its clinical relevance. The effects of changes in L1CAM were investigated in vitro and in vivo. RESULTS: L1CAM was mainly expressed in tumour cells of GC tissues. Elevated L1CAM expression was an independent prognostic factor for overall and disease-free survival, and an independent risk factor for distant metastasis in GC patients. PSM analysis showed that high L1CAM expression was significantly associated with poor prognosis. L1CAM gene expression using fresh frozen specimens successfully validated all of these findings in an independent cohort. Inhibition of L1CAM suppressed cell proliferation, cycle progress, invasion, migration and anoikis resistance in GC cells. Furthermore, L1CAM inhibition suppressed the growth of peritoneal
  • 168 Draft2.Qxd

    168 Draft2.Qxd

    Issue #168 May 2003 Cosmopolis Don DeLILLO 224pp Pb $30.00 Blackwell Month Eric Parker, 28, compassionless and outrageously wealthy, always gets his way. On this day, he is intent on getting his haircut. The traffic is locked tight Buy any Blackwell title this month and go in due to a visit from the President, the funeral of an idolised rapper and an the draw to win your selection of Blackwell intense anti-globalisation protest, which is getting violent in downtown New Publishing books to the value of $300. York. Things seem to be getting out of hand and this invigorates Parker, who We stock a large range of Blackwell Publishing titles, especially in the areas of feels an arrogant superiority amongst the people. Against the advice of his Philosophy, History and Ancient History. Here are some of our most popular titles: personal Chief of Security, who claims his life may be in danger (Parker has Anarchy, State and Utopia by Robert Nozick (Pb $77.00) hundreds of employees, even a doctor who does daily check-ups on him), A Brief History of Heaven by Alister McGrath (Pb $31.85) he gets in his long white limo and directs his driver across town on this A Brief History of Heresy by Gill Evans (Pb $31.85) fateful day. Delillo's new novel is a forewarning of things to come, a surreal Deciphering the Dead Sea Scrolls by Jonathan Campbell (Pb $46.10) and poetic story of the modern world and where it may be Hellenistic Civilization by Francois Chamoux (Pb $63.70) heading.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • L1 Induces Colon Cancer Metastasis but Not EMT and CSC Markers

    L1 Induces Colon Cancer Metastasis but Not EMT and CSC Markers

    Author Manuscript Published OnlineFirst on December 1, 2010; DOI: 10.1158/1541-7786.MCR-10-0406 Author manuscripts havePublished been peer reviewed OnlineFirst and accepted on December for publication 1, 2010but have not yet been edited. L1 induces colon cancer metastasis but not EMT and CSC markers L1-mediated Colon Cancer Cell Metastasis does not Require Changes in EMT and Cancer Stem Cell Markers Nancy Gavert1, Alessia Vivanti1, John Hazin1, Thomas Brabletz2, and Avri Ben-Ze’ev1 1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 76100, Israel 2Department of Visceral Surgery, University of Freiburg, Hugstetter Str 55, Freiburg, 79095, Germany Running title: L1 induces colon cancer metastasis but not EMT and CSC markers Key words: L1, colon cancer, metastasis, EMT, CSC Corresponding author: Avri Ben-Ze’ev Tel: (972)-8-9342422 Fax: (972)-8-9465261 E-mail: [email protected] Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research Downloaded from mcr.aacrjournals.org on October 1, 2021. © 2010 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 1, 2010; DOI: 10.1158/1541-7786.MCR-10-0406 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. L1 induces colon cancer metastasis but not EMT and CSC markers Abstract Aberrant activation of WNT/β-catenin signaling is common in most sporadic and inherited colorectal cancer (CRC) cells leading to elevated β-catenin-TCF transactivation. We previously identified the neural cell adhesion molecule L1 as a target gene of β-catenin- TCF in CRC cells.
  • Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture

    Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture

    Learning from cadherin structures and sequences: affinity determinants and protein architecture Klára Fels ıvályi Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Klara Felsovalyi All rights reserved ABSTRACT Learning from cadherin structures and sequences: affinity determinants and protein architecture Klara Felsovalyi Cadherins are a family of cell-surface proteins mediating adhesion that are important in development and maintenance of tissues. The family is defined by the repeating cadherin domain (EC) in their extracellular region, but they are diverse in terms of protein size, architecture and cellular function. The best-understood subfamily is the type I classical cadherins, which are found in vertebrates and have five EC domains. Among the five different type I classical cadherins, the binding interactions are highly specific in their homo- and heterophilic binding affinities, though their sequences are very similar. As previously shown, E- and N-cadherins, two prototypic members of the subfamily, differ in their homophilic K D by about an order of magnitude, while their heterophilic affinity is intermediate. To examine the source of the binding affinity differences among type I cadherins, we used crystal structures, analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and electron paramagnetic resonance (EPR) studies. Phylogenetic analysis and binding affinity behavior show that the type I cadherins can be further divided into two subgroups, with E- and N-cadherin representing each. In addition to the affinity differences in their wild-type binding through the strand-swapped interface, a second interface also shows an affinity difference between E- and N-cadherin.
  • CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4

    CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4

    CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4 September 2019 Wellcome Genome Campus, UK Lectures to be held in the Francis Crick Auditorium Lunch and dinner to be held in the Hall Restaurant Poster sessions to be held in the Conference Centre Spoken presentations - If you are an invited speaker, or your abstract has been selected for a spoken presentation, please give an electronic version of your talk to the AV technician. Poster presentations – If your abstract has been selected for a poster, please display this in the Conference Centre on arrival. Conference programme Monday, 2 September 2019 11:45-12:50 Registration 12:50-13:00 Welcome and introductions Leopold Parts, Wellcome Sanger Institute UK 13.00-14.00 Keynote lecture Allan Bradley Kymab, UK 14:00-15:30 Session 1: Understanding impact of coding variations Chair: Leopold Parts, Wellcome Sanger Institute UK 14:00 New approaches for addressing the effect of genetic variation at scale Douglas Fowler University of Washington, USA 14:30 Tools for systematic proactive functional testing of human missense variants Frederick Roth University of Toronto 15:00 The mutational landscape of a prion-like domain Benedetta Bolognesi Institute for Bioengineering of Catalonia, Spain 15:15 Functional determination of all possible disease-associated variants in a region of CARD11 using saturation genome editing Richard James University of Washington, USA 15:30-16:00 Afternoon tea 16:00-17:30 Session 2: Measuring consequences of non-coding variation Chair: Lea Starita, University
  • L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions

    L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions

    International Journal of Molecular Sciences Review L1 Cell Adhesion Molecule in Cancer, a Systematic Review on Domain-Specific Functions Miriam van der Maten 1,2, Casper Reijnen 1,3, Johanna M.A. Pijnenborg 1,* and Mirjam M. Zegers 2,* 1 Department of Obstetrics and Gynaecology, Radboud university medical center, 6525 GA Nijmegen, The Netherlands 2 Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, 6525 GA Nijmegen, The Netherlands 3 Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands * Correspondence: [email protected] (J.M.A.P); [email protected] (M.M.Z.) Received: 24 June 2019; Accepted: 23 August 2019; Published: 26 August 2019 Abstract: L1 cell adhesion molecule (L1CAM) is a glycoprotein involved in cancer development and is associated with metastases and poor prognosis. Cellular processing of L1CAM results in expression of either full-length or cleaved forms of the protein. The different forms of L1CAM may localize at the plasma membrane as a transmembrane protein, or in the intra- or extracellular environment as cleaved or exosomal forms. Here, we systematically analyze available literature that directly relates to L1CAM domains and associated signaling pathways in cancer. Specifically, we chart its domain-specific functions in relation to cancer progression, and outline pre-clinical assays used to assess L1CAM. It is found that full-length L1CAM has both intracellular and extracellular targets, including interactions with integrins, and linkage with ezrin. Cellular processing leading to proteolytic cleavage and/or exosome formation results in extracellular soluble forms of L1CAM that may act through similar mechanisms as compared to full-length L1CAM, such as integrin-dependent signals, but also through distinct mechanisms.
  • Cldn19 Clic2 Clmp Cln3

    Cldn19 Clic2 Clmp Cln3

    NewbornDx™ Advanced Sequencing Evaluation When time to diagnosis matters, the NewbornDx™ Advanced Sequencing Evaluation from Athena Diagnostics delivers rapid, 5- to 7-day results on a targeted 1,722-genes. A2ML1 ALAD ATM CAV1 CLDN19 CTNS DOCK7 ETFB FOXC2 GLUL HOXC13 JAK3 AAAS ALAS2 ATP1A2 CBL CLIC2 CTRC DOCK8 ETFDH FOXE1 GLYCTK HOXD13 JUP AARS2 ALDH18A1 ATP1A3 CBS CLMP CTSA DOK7 ETHE1 FOXE3 GM2A HPD KANK1 AASS ALDH1A2 ATP2B3 CC2D2A CLN3 CTSD DOLK EVC FOXF1 GMPPA HPGD K ANSL1 ABAT ALDH3A2 ATP5A1 CCDC103 CLN5 CTSK DPAGT1 EVC2 FOXG1 GMPPB HPRT1 KAT6B ABCA12 ALDH4A1 ATP5E CCDC114 CLN6 CUBN DPM1 EXOC4 FOXH1 GNA11 HPSE2 KCNA2 ABCA3 ALDH5A1 ATP6AP2 CCDC151 CLN8 CUL4B DPM2 EXOSC3 FOXI1 GNAI3 HRAS KCNB1 ABCA4 ALDH7A1 ATP6V0A2 CCDC22 CLP1 CUL7 DPM3 EXPH5 FOXL2 GNAO1 HSD17B10 KCND2 ABCB11 ALDOA ATP6V1B1 CCDC39 CLPB CXCR4 DPP6 EYA1 FOXP1 GNAS HSD17B4 KCNE1 ABCB4 ALDOB ATP7A CCDC40 CLPP CYB5R3 DPYD EZH2 FOXP2 GNE HSD3B2 KCNE2 ABCB6 ALG1 ATP8A2 CCDC65 CNNM2 CYC1 DPYS F10 FOXP3 GNMT HSD3B7 KCNH2 ABCB7 ALG11 ATP8B1 CCDC78 CNTN1 CYP11B1 DRC1 F11 FOXRED1 GNPAT HSPD1 KCNH5 ABCC2 ALG12 ATPAF2 CCDC8 CNTNAP1 CYP11B2 DSC2 F13A1 FRAS1 GNPTAB HSPG2 KCNJ10 ABCC8 ALG13 ATR CCDC88C CNTNAP2 CYP17A1 DSG1 F13B FREM1 GNPTG HUWE1 KCNJ11 ABCC9 ALG14 ATRX CCND2 COA5 CYP1B1 DSP F2 FREM2 GNS HYDIN KCNJ13 ABCD3 ALG2 AUH CCNO COG1 CYP24A1 DST F5 FRMD7 GORAB HYLS1 KCNJ2 ABCD4 ALG3 B3GALNT2 CCS COG4 CYP26C1 DSTYK F7 FTCD GP1BA IBA57 KCNJ5 ABHD5 ALG6 B3GAT3 CCT5 COG5 CYP27A1 DTNA F8 FTO GP1BB ICK KCNJ8 ACAD8 ALG8 B3GLCT CD151 COG6 CYP27B1 DUOX2 F9 FUCA1 GP6 ICOS KCNK3 ACAD9 ALG9
  • 2021 Code Changes Reference Guide

    2021 Code Changes Reference Guide

    Boston University Medical Group 2021 CPT Code Changes Reference Guide Page 1 of 51 Background Current Procedural Terminology (CPT) was created by the American Medical Association (AMA) in 1966. It is designed to be a means of effective and dependable communication among physicians, patients, and third-party payers. CPT provides a uniform coding scheme that accurately describes medical, surgical, and diagnostic services. CPT is used for public and private reimbursement systems; development of guidelines for medical care review; as a basis for local, regional, and national utilization comparisons; and medical education and research. CPT Category I codes describe procedures and services that are consistent with contemporary medical practice. Category I codes are five-digit numeric codes. CPT Category II codes facilitate data collection for certain services and test results that contribute to positive health outcomes and quality patient care. These codes are optional and used for performance management. They are alphanumeric five-digit codes with the alpha character F in the last position. CPT Category III codes represent emerging technologies. They are alphanumeric five-digit codes with the alpha character T in the last position. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is responsible for maintaining and updating the CPT code set. Purpose The AMA makes annual updates to the CPT code set, effective January 1. These updates include deleted codes, revised codes, and new codes. It’s important for providers to understand the code changes and the impact those changes will have to systems, workflow, reimbursement, and RVUs. This document is meant to assist you with this by providing a summary of the changes; a detailed breakdown of this year’s CPT changes by specialty, and HCPCS Updates for your reference.
  • Strategic Plan 2011-2016

    Strategic Plan 2011-2016

    Strategic Plan 2011-2016 Wellcome Trust Sanger Institute Strategic Plan 2011-2016 Mission The Wellcome Trust Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health. -i- Wellcome Trust Sanger Institute Strategic Plan 2011-2016 - ii - Wellcome Trust Sanger Institute Strategic Plan 2011-2016 CONTENTS Foreword ....................................................................................................................................1 Overview .....................................................................................................................................2 1. History and philosophy ............................................................................................................ 5 2. Organisation of the science ..................................................................................................... 5 3. Developments in the scientific portfolio ................................................................................... 7 4. Summary of the Scientific Programmes 2011 – 2016 .............................................................. 8 4.1 Cancer Genetics and Genomics ................................................................................ 8 4.2 Human Genetics ...................................................................................................... 10 4.3 Pathogen Variation .................................................................................................. 13 4.4 Malaria
  • Fiona Fox Chief Execu�Ve

    Fiona Fox Chief ExecuVe

    Fiona Fox Chief Execu+ve Set up in 2002 aer things went very wrong: - MMR & au;sm - GM crops - BSE - Animal research AIMS Vision Policy decisions and public debate informed by accurate, evidence-based scien7fic informaon in the news media Mission To make it easier for journalists to access the best science when stories hit the headlines and to ensure that more scien7sts engage with the media when stories hit the headlines Values Reliable, fast, accurate, authoritave, independent, media savvy SMC Philosophy " We’ll get the media to ‘DO’ science better when scientists ‘DO’ media better " Animal research in the UK media 1. The Bad Old Days Reac;ng to animal extremism 1980s – 1990s - Almost every story is on extremism - Only a handful of scien;sts prepared to speak out - Animal research covered by general and polical reporters - Funders and government stay quiet Legislave, judicial & Animal ac;vist / extremist ac;vity Science & medical governmental acon community acon 1997 (July) Consort Kennels in Hereford, a laboratory beagle breeder, closes aer a 10-month animal rights campaign including the theG of 26 beagles. 1999 (August) Hillgrove Farm in Oxfordshire, the UK's only commercial breeder of laboratory cats, closes aer a violent three year campaign. (Jan) Cambridge University abandons plan 2004 for new primate laboratory aer intense campaigning. (Oct) Darley Oaks Farm in Staffordshire closes its guinea pig breeding business aer a violent six-year campaign including digging up the grave of Gladys Hammond, the owners’ mother-in-law, sparking